# An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

> **NCT00191737** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 147 (—)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine

## Key facts

- **NCT ID:** NCT00191737
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 147 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191737, "An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00191737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*